ANZUP 1901: A randomised phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide

  • Zhang, Alison (Primary Chief Investigator)
  • Chapman, Nicola (Clinical Trial Unit Staff)

Project: Research

Project Details

AcronymENZA-P
StatusActive
Effective start/end date26/10/21 → 22/10/25